Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a Phase I/II study


Year:

Session type:

Martin Forster1, David Olmos1, Sophia Frentzas1, Shahneen Sandhu1, Tim Yap1, Daniel Tan1, Jorge Barriuso1, Michelle Wright1, Morris Groves2, David Reardon3, Martin Curtis4, Jeffrey Hodge4, Ben Suttle4, B Ma4, Joanne Lager4, Johann de Bono1

1Royal Marsden Hospital, Sutton, UK, 2M.D. Anderson, Houston, Texas, USA, 3Duke University Medical Centre, Durham, USA, 4GlaxoSmithKline, Research Triangle Park, USA

Abstract

Background

Pazopanib (paz) is an oral angiogenesis inhibitor targeting VEGFR, PDGFR, and c-kit; lapatinib (lap) is an oral tyrosine kinase inhibitor of EGFR and HER2. The combination may provide synergistic activity in malignant glioma. The efficacy of daily paz/lap (400mg/1000mg) in relapsed grade 4 glioma was previously reported. This study determined the optimally tolerated regimen (OTR) of paz/lap when given with enzyme-inducing anticonvulsants (EIACs).

Method

Patients (pts) with Grade 3 or 4 glioma were treated with escalating doses of paz/lap in a 3+3 design.